Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Authors
Keywords
-
Journal
Biomed Research International
Volume 2018, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2018-05-11
DOI
10.1155/2018/4839230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eosinophilic and Noneosinophilic Asthma
- (2018) Tara F. Carr et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
- (2018) Bradley E. Chipps et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Important and specific role for basophils in acute allergic reactions
- (2018) P. Korošec et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma
- (2018) Maciej Kupczyk et al. Immunotherapy
- Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma
- (2018) Roma Sehmi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Asthma
- (2018) Alberto Papi et al. LANCET
- Asthma and corticosteroids: time for a more precise approach to treatment
- (2017) Eleanor M. Dunican et al. EUROPEAN RESPIRATORY JOURNAL
- Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children
- (2017) Corrado Pelaia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma
- (2017) Maria Gabriella Matera et al. Expert Opinion on Drug Metabolism & Toxicology
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe and Difficult-to-Treat Asthma in Adults
- (2017) Elliot Israel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
- (2017) Corrado Pelaia et al. Drug Design Development and Therapy
- Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Gary T Ferguson et al. Lancet Respiratory Medicine
- Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials
- (2017) Ting Liu et al. Frontiers of Medicine
- Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3
- (2016) Konrad Pazdrak et al. APOPTOSIS
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders
- (2016) Gilda Varricchi et al. Current Opinion in Allergy and Clinical Immunology
- A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan
- (2016) Hae-Sim Park et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma
- (2016) MirHojjat Khorasanizadeh et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia
- (2016) Steven G. Smith et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Current concepts of severe asthma
- (2016) Anuradha Ray et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma
- (2016) Girolamo Pelaia et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Reductions in eosinophil biomarkers by benralizumab in patients with asthma
- (2016) Tuyet-Hang Pham et al. RESPIRATORY MEDICINE
- The clinical profile of benralizumab in the management of severe eosinophilic asthma
- (2016) Francesco Menzella et al. Therapeutic Advances in Respiratory Disease
- Role of biologics in severe eosinophilic asthma – focus on reslizumab
- (2016) Girolamo Pelaia et al. Therapeutics and Clinical Risk Management
- A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma
- (2015) Richard M. Nowak et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
- (2015) Girolamo Pelaia et al. MEDIATORS OF INFLAMMATION
- The immunology of asthma
- (2015) Bart N Lambrecht et al. NATURE IMMUNOLOGY
- Prevalence of eosinophilia in hospitalized patients with asthma exacerbation
- (2015) Kohei Hasegawa et al. RESPIRATORY MEDICINE
- Asthma
- (2015) Stephen T. Holgate et al. Nature Reviews Disease Primers
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
- (2014) Mario Castro et al. Lancet Respiratory Medicine
- Eosinophilic asthma: Insights into the effects of reducing IL-5 receptor–positive cell levels
- (2013) Amal H. Assa'ad et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma
- (2013) Guy G Brusselle et al. NATURE MEDICINE
- Targeting eosinophils in allergy, inflammation and beyond
- (2013) Patricia C. Fulkerson et al. NATURE REVIEWS DRUG DISCOVERY
- Update on Anticytokine Treatment for Asthma
- (2013) Luca Gallelli et al. Biomed Research International
- The potential of biologics for the treatment of asthma
- (2012) Girolamo Pelaia et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor
- (2011) N. A. Molfino et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
- (2011) Aasia Ghazi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
- (2010) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
- (2009) Prescott G. Woodruff et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- IL-5 and eosinophilia
- (2008) Kiyoshi Takatsu et al. CURRENT OPINION IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation